Sarcoma treatment in the era of molecular medicine
Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers.
Although constituting only 1% of all human malignancies, sarcomas represent the second …
Although constituting only 1% of all human malignancies, sarcomas represent the second …
[HTML][HTML] The role of photoactivated and non-photoactivated verteporfin on tumor
C Wei, X Li - Frontiers in pharmacology, 2020 - frontiersin.org
Verteporfin (VP) has long been clinically used to treat age-related macular degeneration
(AMD) through photodynamic therapy (PDT). Recent studies have reported a significant anti …
(AMD) through photodynamic therapy (PDT). Recent studies have reported a significant anti …
[HTML][HTML] Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma
R Berthold, I Isfort, C Erkut, L Heinst, I Grünewald… - Oncogenesis, 2022 - nature.com
Myxoid liposarcoma (MLS) represents a common subtype of liposarcoma molecularly
characterized by a recurrent chromosomal translocation that generates a chimeric FUS …
characterized by a recurrent chromosomal translocation that generates a chimeric FUS …
[HTML][HTML] AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis
Hippo signaling functions to limit cellular growth, but the aberrant nuclear accumulation of its
downstream YAP1 leads to carcinogenesis. YAP1/TEAD complex activates the oncogenic …
downstream YAP1 leads to carcinogenesis. YAP1/TEAD complex activates the oncogenic …
[HTML][HTML] Metabolic landscapes in sarcomas
Metabolic rewiring offers novel therapeutic opportunities in cancer. Until recently, there was
scant information regarding soft tissue sarcomas, due to their heterogeneous tissue origin …
scant information regarding soft tissue sarcomas, due to their heterogeneous tissue origin …
[HTML][HTML] YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer
JH Driskill, JK Dermawan… - Annual Review of …, 2024 - annualreviews.org
Gene fusions are well-known drivers of cancer and are potent targets for molecular therapy.
An emerging spectrum of human tumors harbors recurrent and pathognomonic gene fusions …
An emerging spectrum of human tumors harbors recurrent and pathognomonic gene fusions …
Prognostic value of nuclear morphometry in myxoid liposarcoma
K Kawaguchi, K Kohashi, T Iwasaki… - Cancer …, 2023 - Wiley Online Library
Myxoid liposarcoma (MLS) accounts for 20%‐30% of liposarcoma and the round cell
component (RCC) is believed to be a specific poor prognostic factor. However, the RCC …
component (RCC) is believed to be a specific poor prognostic factor. However, the RCC …
[HTML][HTML] FUS-DDIT3 fusion oncoprotein expression affects JAK-STAT signaling in myxoid liposarcoma
S Dolatabadi, E Jonasson, L Andersson… - Frontiers in …, 2022 - frontiersin.org
Myxoid liposarcoma is one of the most common sarcoma entities characterized by FET
fusion oncogenes. Despite a generally favorable prognosis of myxoid liposarcoma …
fusion oncogenes. Despite a generally favorable prognosis of myxoid liposarcoma …
[HTML][HTML] A review of retroperitoneal liposarcoma genomics
R Tyler, K Wanigasooriya, P Taniere, M Almond… - Cancer treatment …, 2020 - Elsevier
Retroperitoneal liposarcomas are rare tumours that carry a poorer prognosis than their
extremity counterparts. Within their subtypes–well differentiated (WDL), dedifferentiated …
extremity counterparts. Within their subtypes–well differentiated (WDL), dedifferentiated …
[HTML][HTML] Genetic, epigenetic and transcriptome alterations in liposarcoma for target therapy selection
EA Lesovaya, TI Fetisov, BY Bokhyan, VP Maksimova… - Cancers, 2024 - mdpi.com
Simple Summary Liposarcoma is the most widespread soft-tissue sarcoma in adults. This
review summarizes the molecular genetics and epigenetics of the main liposarcoma …
review summarizes the molecular genetics and epigenetics of the main liposarcoma …